Treatment of Generalized Tonic-Clonic Seizures in the Modern Era (Transcript)

You are leaving Medscape Education

Cancel Continue

CME & Education

Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-521. Abstract
Nicolson A, Appleton RE, Chadwick DW, et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry. 2004;75:75-79. Abstract
Engel J Jr. What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture. Neurology. 2016;87:2483-2489. Abstract
Benbadis SR, Tatum WO, Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology. 2003;61:1793-1795. Abstract
Bajacek M, Hovorka J, Nezadal T, et al. Is pseudo-intractability in population of patients with epilepsy still alive in the 21st century? Audit of 100 seizure-free patients, referred with the diagnosis of pharmacoresistant epilepsy. Neuro Endocrinol Lett. 2010;31:818-822. Abstract
Brodie MJ. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016;16:82.
Shih JJ, Whitlock JB, Chimato N, et al. Epilepsy treatment in adults and adolescents: expert opinion. Epilepsia. 2017;69:186-222.
Drugs for epilepsy. Med Lett Drugs Ther. 2017; 59. In press.
French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85:950-957. Abstract
Wechsler RT, Yates SL, Messenheimer J, et al. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension. Epilepsy Res. 2017;130:13-20. Abstract
Velizarova R, Crespel A, Genton P, et al. Zonisamide for refractory juvenile absence epilepsy. Epilepsy Res. 2014;108:1263-1266. Abstract
Meador KJ, Loring DW. Developmental effects of antiepileptic drugs and the need for improved regulations. Neurology. 2016;86:297-306. Abstract
Jones LA, Thomas RH. Sudden death in epilepsy: insights from the last 25 years. Seizure. 2017;44:232-236. Abstract

CME / ABIM MOC / CE

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Authors: Gregory L. Krauss, MD; Jerry J. Shih, MD; Imad Najm, MD
CME / ABIM MOC / CE Released: 5/26/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/26/2018, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, pediatricians, primary care physicians, and nurses.

The goal of this activity is to provide an overview of generalized seizures with regard to factors that differentiate generalized from focal seizures and available treatments for generalized tonic-clonic seizures.

Upon completion of this activity, learners will demonstrate increased knowledge regarding:

Goals of treatment for patients diagnosed with generalized epilepsy
Strategies for optimizing the management of drug-resistant generalized epilepsy

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Gregory L. Krauss, MD

Professor of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Disclosures

Participation by Dr Krauss does not constitute or imply endorsement by The Johns Hopkins University or The Johns Hopkins Hospital and Health System.

Disclosure: Gregory L. Krauss, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Inc.
Received grants for clinical research from: Pfizer Inc; SK Biopharmaceuticals Co., Ltd.; UCB Pharma, Inc.; Upsher-Smith Laboratories, Inc.

Dr Krauss does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Krauss does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Jerry J. Shih, MD

Director, Comprehensive Epilepsy Center, UC San Diego Health, La Jolla, California

Disclosures

Disclosure: Jerry J. Shih, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Eisai Inc.

Dr Shih does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Shih does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Imad Najm, MD

Director, Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio

Disclosures

Disclosure: Imad Najm, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Sunovion Pharmaceuticals Inc.

Dr Najm does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Najm does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

Tracy A. Glauser, MD

Professor of Pediatrics and Neurology, University of Cincinnati College of Medicine; Director, Comprehensive Epilepsy Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Disclosures

Disclosure: Tracy A. Glauser, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; UCB Pharma, Inc.
Owns stock, stock options, or bonds from: AssureRx Health, Inc.

Gregory L. Krauss, MD

Disclosures

As listed above

Imad Najm, MD

Disclosures

As listed above

Joseph I. Sirven, MD

Professor and Chairman, Department of Neurology, Mayo Clinic Hospital, Phoenix, Arizona

Disclosures

Disclosure: Joseph I. Sirven, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acorda Therapeutics; UCB Pharma, Inc.
Received grants for clinical research from: NeuroPace, Inc.

John M. Stern, MD

Professor of Neurology, David Geffen School of Medicine, University of California, Los Angeles

Disclosures

Disclosure: John M. Stern, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Cyberonics, Inc.; Eisai Inc.; Lundbeck, Inc.; Sunovion Pharmaceuticals Inc.; UCB Pharma, Inc.

James Wheless, MD

Professor; Chief of Pediatric Neurology; Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science Center; Director, Le Bonheur Comprehensive Epilepsy Program and Neuroscience Institute, Le Bonheur Children's Hospital, Memphis, Tennessee

Disclosures

Disclosure: James Wheless, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: CombiMatrix; Eisai Inc.; GW Pharmaceuticals; Lundbeck, Inc.; NeuroPace, Inc.; Supernus Pharmaceuticals, Inc.; Upsher-Smith Laboratories, Inc.
Served as a speaker or a member of a speakers bureau for: Cyberonics, Inc.; Eisai Inc.; Lundbeck, Inc.; Mallinckrodt Pharmaceuticals; Questcor Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Upsher-Smith Laboratories, Inc.
Received grants for clinical research from: Acorda Therapeutics; GW Pharmaceuticals; INSYS Therapeutics, Inc.; Lundbeck, Inc.; Mallinckrodt Pharmaceuticals; Neuralis; Upsher-Smith Laboratories, Inc.; Zogenix, Inc.

Editor(s)

Gena Dolson, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Gena Dolson, MS, has disclosed no relevant financial relationships.

Catherine Friederich Murray, BS

Associate Scientific Director, Medscape, LLC

Disclosures

Disclosure: Catherine Friederich Murray, BS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME / ABIM MOC / CE

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Authors: Gregory L. Krauss, MD; Jerry J. Shih, MD; Imad Najm, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 5/26/2017

Valid for credit through: 5/26/2018, 11:59 PM EST

processing....

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Gregory L. Krauss, MD

Panelists

Jerry J. Shih, MD

Imad Najm, MD

Steering Committee

Tracy A. Glauser, MD

Gregory L. Krauss, MD

Imad Najm, MD

Joseph I. Sirven, MD

John M. Stern, MD

James Wheless, MD

Editor(s)

Gena Dolson, MS

Catherine Friederich Murray, BS

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME / ABIM MOC / CE

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Target Audience and Goal Statement

Disclosures

Moderator

Gregory L. Krauss, MD

Panelists

Jerry J. Shih, MD

Imad Najm, MD

Steering Committee

Tracy A. Glauser, MD

Gregory L. Krauss, MD

Imad Najm, MD

Joseph I. Sirven, MD

John M. Stern, MD

James Wheless, MD

Editor(s)

Gena Dolson, MS

Catherine Friederich Murray, BS

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era